Impact of telephone follow-up on hepatocellular carcinoma patients receiving oral chemotherapy from an ambulatory-care setting.
| Autor: | Sakata Y; Department of Pharmacy, Hakodate Municipal Hospital, Hakodate, Hokkaido, Japan., Nomura H; Department of Pharmacy, National Cancer Center Hospital East, Kashiwa, Chiba, Japan.; Clinical Research Support Office, Seeds Development Promotion Department, National Cancer Center Hospital East, Kashiwa, Chiba, Japan., Nakajima H; Department of Pharmacy, Hakodate Municipal Hospital, Hakodate, Hokkaido, Japan., Kitajima T; Department of Nursing, Hakodate Municipal Hospital, Hakodate, Hokkaido, Japan., Ito Y; Department of Nursing, Hakodate Municipal Hospital, Hakodate, Hokkaido, Japan., Yamamoto Y; Department of Gastroenterology and Hepatology, Hakodate Municipal Hospital, Hakodate, Hakodate, Japan. |
|---|---|
| Jazyk: | angličtina |
| Zdroj: | Journal of oncology pharmacy practice : official publication of the International Society of Oncology Pharmacy Practitioners [J Oncol Pharm Pract] 2024 Dec; Vol. 30 (8), pp. 1378-1384. Date of Electronic Publication: 2023 Dec 03. |
| DOI: | 10.1177/10781552231215427 |
| Abstrakt: | Introduction: In recent years, most molecular target drugs have been administered orally, as prescribed at ambulatory services in hospitals and at patients' homes. Telephone follow-up is increasingly being used in clinical practice for patients needing additional support post-discharge and for the prevention of hospital readmissions. The purpose of this study was to clarify the clinical benefits of telephone follow-up while administering oral anticancer drugs. Methods: This was a single-center, observational, retrospective study. We evaluated hepatocellular carcinoma patients who received sorafenib or lenvatinib between March 2010 and February 2018. The primary endpoint was the incidence of adverse events. Results: From the total of 130 patients, 83 patients received telephone follow-up and 47 did not. The incidence of hand-foot skin reactions significantly reduced in patients with telephone follow-up (odds ratio (OR) 3.69, 95% confidence interval (CI) 1.16-11.8, p = 0.020). The median durations (ranges) of adherence to oral chemotherapy were 259 days (15-1730) for the telephone follow-up group and 121 days (14-1105) for the no-telephone follow-up group ( p < 0.001). Moreover, the disease control rate was significantly higher in the telephone follow-up group (OR 2.52, 95% CI 1.15-5.53, p = 0.020). Conclusions: Remote interventions, such as telephone follow-up, are useful means of managing adverse events in patients receiving oral anticancer drugs and can lead to improved treatment results. Competing Interests: Declaration of conflicting interestsThe authors declared no potential conflicts of interest with respect to the research, authorship, and/or publication of this article. |
| Databáze: | MEDLINE |
| Externí odkaz: |
|